Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 77 guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Primary Cutaneous Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Penile Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Penile Cancer, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Patient Indications for Mohs Micrographic Surgery

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations on the use of Mohs micrographic surgery (MMS) for adult patients diagnosed with skin cancer. MMS is compared to other surgical excision techniques, as well as other treatment modalities such as radiation. Guidance is provided on the indications and considerations for appropriate use of MMS, including disease stage, aesthetic outcomes, patient comorbidities, and patient preferences. Outcomes of interest include cure rate, recurrence rate, quality of life, and adverse events.

Merkel Cell Carcinoma, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.

Primary Cutaneous B-Cell Lymphomas, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, work-up, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2018
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the prevention and screening of skin cancer. Behavioural counselling recommendations are provided for young adults, adolescents, children, and parents of young children. Outcomes of interest include changes in sun protection behaviours, frequency of sunburn, and frequency of skin cancer.

Vulvar Cancer (Squamous Cell Carcinoma), Version 1.2018

Year: 2017
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

Primary Excision Margins and Sentinel Lymph Node Biopsy in Cutaneous Melanoma

Year: 2017
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults diagnosed non-metastatic cutaneous melanoma, located on the trunk, extremities, or head and neck. The guideline examines optimal excision margins and the use of sentinel lymph node biopsy (SLNB) in these patients. The recommendations are organized by location of melanoma on the body, and consider the thickness/depth of the melanoma. Outcomes of interest include recurrence rate, survival rate, morbidity, and rate of sentinel lymph node positivity.

Guidelines of Care for the Management of Cutaneous Squamous Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.

Guidelines of Care for the Management of Basal Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.

Squamous Cell Skin Cancer – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for squamous cell skin cancer. Basal cell and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSCs), are the most common cancer in the United States. The guideline provides recommendations related to clinical presentation and workup, local treatment, recurrence and metastasis, and follow-up. The guideline also provides a discussion about risk stratification and common risk factors including age, degree of differentiation, and site of prior radiotherapy.

British Association of Dermatologists’ Guidelines for the Care of Patients With Actinic Keratosis 2017

Year: 2017
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with actinic keratosis (AK). The guideline provides recommendations on treatment options such as topical therapies, cryosurgery, surgery, systemic therapy, photodynamic therapy, laser therapy, and combination treatment. Diagnosis and follow-up are also discussed.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with melanoma. The guideline examines the use of sentinel lymph node (SLN) biopsy as a method for identifying nodal metastases, and provides recommendations on which patients should receive SLN biopsy based on the size and morphology of their melanoma. The guideline also discusses the appropriateness of completion lymph node dissection (CLND) as a method of treatment.

Merkel Cell Carcinoma – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for merkel cell carcinoma. Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma. This guideline provides recommendations for diagnosis and workup, staging, treatment, follow-up and recurrence. Treatment recommendations include surgery, sentinel lymph node biopsy, radiation therapy, and chemotherapy as possible options.

Cutaneous Melanoma: A National Clinical Guideline

Year: 2017
AGREE II score: Available
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

Basal Cell Skin Cancer – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for basal cell skin cancer. The guideline considers clinical presentation and workup, local treatment, recurrence and metastasis, and follow-up. The guideline also includes a discussion about risk stratification and explores different risk factors for basal cell skin cancer including location and size, age, and site of prior radiotherapy.

Surgical Management of Patients With Lymph Node Metastases from Cutaneous Melanoma of the Trunk or Extremities

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with cutaneous melanoma of the trunk or extremities. The guideline examines the optimal surgical management of patients with positive sentinel lymph nodes (SLNs) and biopsy-proven clinically palpable or biopsy-proven radiologically detected lymph nodes from cutaneous melanoma originating in the trunk or extremities. Outcomes of interest include local and regional recurrence, distant recurrence, overall survival (OS), and disease-free survival (DFS).

Screening for Skin Cancer: US Preventive Services Task force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is an update to the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for skin cancer. The guideline specifically addresses evidence on the effectiveness of screening for skin cancer with a clinical visual skin examination in reducing skin cancer morbidity and mortality and death from any cause; its potential harms, including any harms resulting from associated diagnostic follow-up; its test characteristics when performed by a primary care clinician vs a dermatologist; and whether its use leads to earlier detection of skin cancer compared with usual care.

Sentinel Node Biopsy in Primary Cutaneous Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews the use of sentinel node biopsy (SLNB) as a diagnostic tool for adult patients with malignant melanoma. Topics of discussion include indications and contraindications of SLNB, pathological examination of the sentinel nodes, and indications for therapeutic node dissection and recommended extent of dissection. The use of ultrasound-guided fine-needle aspiration is also discussed. Outcomes of interest include test sensitivity, specificity, and positive and negative predictive value, as well as rate of nodal recurrence and survival.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the clinical management of malignant melanoma with the aim of improving the standard of care received by this patient population. The guideline provides recommendations on referral to surgeons and associated wait times, procedures (e.g., biopsy), tumour markers, and adjuvant therapies.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the management of malignant melanoma. Topics of interest include acceptable time intervals from referral to surgical management, which patients should be candidates for sentinel lymph node biopsy, and acceptable surgical margins.

Screening for Skin Cancer US Preventive Services Task Force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the screening of skin cancer in asymptomatic adults. The recommendations do not apply to patients with suspicious skin lesions, family history of skin cancer, or personal history of pre-malignant or malignant skin lesions. Outcomes of interest include reductions in morbidity and mortality from skin cancers.

The Use of Adjuvant Radiation Therapy for Curatively Resected Melanoma

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with stage 1-3 cutaneous melanoma who have received curative resection. The guideline examines the appropriateness of adjuvant radiation therapy (RT) for these patients, narrowing the focus on those patients with primary melanoma, in-transit primary melanoma, recurrent melanoma, and those at high risk for regional recurrence of melanoma. The guideline also considers whether equivalent disease control is provided with a standard fractionation schedule and a hypofractionated schedule. Outcomes of interest include control rate, survival rate and adverse event rates.

Fertility Drugs and Cancer: A Guideline

Year: 2016
AGREE II score: Unavailable
Developer organization: American Society for Reproductive Medicine
This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

Clinical Practice Guidelines for the Diagnosis and Management of Melanoma

Year: 2016
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for the diagnosis and management of melanoma. The purpose of these guidelines is to achieve early diagnosis whenever possible, make doctors and patients aware of the most effective treatment options, and minimize the financial burden on the health system by documenting investigations and therapies that are inappropriate. Topics discussed include: features of melanoma, biopsy, sentinel node biopsy, and excision margins.

Second-Line Treatment of Metastatic Melanoma with Ipilimumab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the second line treatment of metastatic melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy ipilimumab. The treatment intent of this guideline is non-curative and to improve overall survival, as well as progression free survival.

First-Line Treatment of BRAF V600 Mutated Metastatic Melanoma with Vemurafenib

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of mutated metastatic melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy vemurafenib. The treatment intent of this guideline is non-curative and to improve overall survival, as well as progression free survival.

Non-Melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-Melanoma Skin Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the primary prevention of non-melanoma skin cancer, including basal and squamous cell carcinoma. The guideline examines modifiable risk factors for developing skin cancer, focusing primarily on photoprotection at an individual and public health level. Outcomes of interest include reduced actinic keratoses through daily sunscreen use and clarification of labelling standards. This guideline is Chapter 2 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Melanoma: Assessment and Management

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline is for patients diagnosed with or suspected of having melanoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Follow-up care is also discussed, including topics such as management of suboptimal Vitamin D levels and concurrent drug therapies. Outcomes of interest include survival (overall, disease free, melanoma specific), and adverse events (acute toxicity, wound/sensory complications).

Non-Melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the treatment of actinic keratosis and cheilitis as precursors to invasive squamous cell carcinomas. The guideline examines treatment options including surgical and topical removal, and considers the use of combined modalities. There is also specific information for the monitoring and treatment of long-term immunosuppressed patients. Outcomes of interest include improved cosmetic results through the use of topical methods. This guideline is Chapter 3 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Dermatofibrosarcoma Protuberans, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for dermatofibrosarcoma protuberans (DFSP). The NCCN Non-Melanoma Skin Cancer Panel has developed these guidelines outlining the treatment of DFSP to supplement their guidelines for basal cell and squamous cell skin cancers and merkel cell carcinoma. Topic areas discussed in this guideline as they relate to DFSP include: biopsy, surgery, chemotherapy, and radiotherapy.

Treatment of BRAF V600 Mutated Advanced Melanoma with Trametinib

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of mutated advanced melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy trametinib. The treatment intent is to improve quality of life and decrease symptom burden.

Guidelines of the Brazilian Dermatology Society for Diagnosis, Treatment and Follow Up of Primary Cutaneous Melanoma – Part I

Year: 2015
AGREE II score: Unavailable
Developer organization: Brazilian Dermatology Society
A clinical practice guideline for patients with primary cutaneous melanoma. The guideline examines the use of dermoscopy for diagnosis, and treatment including appropriate surgical margins. Outcomes of interest include prognostic improvement, aesthetic impairment, and cure rates.

Oncogenetic Testing, Diagnosis and Follow-up in Birt-Hogg-Dubé Syndrome, Familial Atypical Multiple Mole Melanoma Syndrome and Neurofibromatosis 1 and 2

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients at risk of Birt-Hogge-Dubé Syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2, either based on clinical suspicion or family history. The guideline reviews indications for genetic testing, clinical utility of specific genetic tests, and follow-up depending on test results and family history. Impact of genetic counselling and test on patient behaviour and distress levels is also reviewed.

Follow-up of Patients with Cutaneous Melanoma who were Treated with Curative Intent

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with cutaneous melanoma after treatment with curative intent. The guideline provides recommendations on follow-up schedules, involving appropriate evaluations and timing for early detection of local-regional recurrence, distant metastases, and new primary melanomas. Diagnostic imaging modalities such as ultrasound (US), computed tomography (CT), positron emission tomography (PET), and PET/CT, laboratory tests such as LDH and S100B, skin self-examinations, and dermoscopy/dermatoscopy are discussed.

Non-Melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the staging and treatment of squamous cell carcinoma. The guideline examines treatment options, primarily surgical excision, and provides guidelines for immunocompromised and high-risk patients. Outcomes of interest include improved tissue sparing through Mohs micrographic surgery, and improved understandings of surgical margins. This guideline is Chapter 5 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Non-Melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guide for the staging and treatment of basal cell carcinoma. The guideline examines numerous treatment options, including cryosurgery, topical, and photodynamic approaches. Outcomes of interest include reduced recurrence rates with surgical excision and Mohs micrographic surgery. This guideline is Chapter 4 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Systemic Therapy for Unresectable Stage III or Metastatic Cutaneous Melanoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with unresectable stage III and stage IV cutaneous melanoma, without involvement of the central nervous system (CNS). The guideline reviews the use of BRAF biomarker testing, and provides recommendations for first- and second-line systemic therapy options. BRAF Inhibitors, MEK inhibitors, immune checkpoint Inhibitors, other biological agents (e.g. imatinib and bevacizumab), and chemotherapy agents are reviewed.

Merkel Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with Merkel cell carcinoma of the skin. The guideline provides recommendations on staging and work-up, treatment options including surgery, radiation, and chemotherapy, and follow-up care. The guideline also provides recommendations on management of recurrences, and reviews sentinel lymph node biopsy protocol.

Suspected Cancer: Recognition and Referral

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.

Adjuvant Interferon for Malignant Melanoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults with malignant melanoma. The guideline considers whether adjuvant interferon alpha should be offered to patients who have been rendered disease-free following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence. Issues discussed include: steps of treatment, potential side effects, special considerations (such as toxicity, and patient education), and follow-up.

The American Brachytherapy Society Consensus Guidelines for Plaque Brachytherapy of Uveal Melanoma and Retinoblastoma

Year: 2014
AGREE II score: Unavailable
Developer organization: American Brachytherapy Society
A clinical practice guideline for the use of plaque brachytherapy in patients with choroidal melanoma and retinoblastoma. The guideline examines appropriate staging criteria, treatment planning, and alternative surgical and radiation therapy techniques. Outcomes of interest include improved visual acuity and local control.

British Association of Dermatologists’ Guidelines for the Management of Squamous Cell Carcinoma In Situ (Bowen’s Disease) 2014

Year: 2014
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for the diagnosis and treatment of squamous cell carcinoma in situ (Bowen's disease). Various treatment options are compared with attention to invasiveness of therapy and cost, complexity, and general availability of required equipment. Other outcomes of interest include treatment efficacy, aesthetic result, wound healing, and morbidity.

Sentinel Node Biopsy in Primary Cutaneous Melanoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews the use of sentinel node biopsy (SLNB) as a diagnostic tool for adult patients with malignant melanoma. The guideline reviews indications and contraindications of SLNB, pathological examination of the sentinel nodes, and indications for therapeutic node dissection and recommended extent of dissection. The use of ultrasound-guided fine-needle aspiration is also discussed. Outcomes of interest include test sensitivity, specificity, and positive and negative predictive value, as well as rate of nodal recurrence and survival.

British HIV Association Guidelines for HIV-Associated Malignancies 2014

Year: 2014
AGREE II score: Available
Developer organization: British HIV Association
This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.

Required Reports for Referrals

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on required reports for referrals for: breast, gastrointestinal (esophagus, stomach, colon-rectum, anus, pancreas, liver, biliary tract/gall bladder), genitourinary (testis, prostate, bladder), gynecology (endometrium, cervix, ovary, vulva & vagina), head and neck (parotid & submandibular gland, thyroid, mouth, palate, nasopharynx, oropharynx, hypopharynx, nose & antrum, ear), lung, lymphoma and leukemia, melanoma, musculoskeletal and sarcoma, neuro-oncology, primary unknown, and skin (basal cell & squamous cell carcinomas, mycosis fungoides – Sezary syndrome). The guideline provides recommendations on pathology reports, operative reports, laboratory reports, and imaging reports. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Skin Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of skin cancers including melanoma and non-melanoma. Topics of discussion include potential precursors, surveillance and early detection, diagnosis and staging, and management. Additionally, referral information and management policies are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Early Detection of Cancer in AYAs

Year: 2014
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for the early detection of common cancers in adolescents and young adults aged between 15 and 24 years of age. The cancers covered include leukemia, lymphoma, brain tumours, soft tissue sarcoma, testicular cancer, thyroid cancer, and melanoma. The guideline discusses common signs and symptoms and provides recommendations on clinical assessment and referral. "Youth-friendly" communication between practitioner and patient is also discussed, and links for patient and practitioner resources are provided.

The Use of Indoor Tanning Devices and the Risk of Developing Cutaneous Malignant Melanoma: A Systematic Review and Clinical Practice Guideline

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients at risk of developing melanoma due to the use of indoor tanning devices. The guideline examines risk due to use, impact of age, and frequency of use as it relates to cutaneous malignant melanoma. Outcomes of interest include relative risk and increased risk.

Update of the European Guidelines for Basal Cell Carcinoma Management

Year: 2014
AGREE II score: Unavailable
Developer organization: European Dermatology Forum
This is a clinical practice guideline for patients diagnosed with or suspected of having basal cell carcinoma. The guideline reviews prognosis and risk factors, diagnosis, treatment, follow-up care, and prevention. Outcomes of interest include cure rate, recurrence, cost-effectiveness, and response rate.

Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis

Year: 2014
AGREE II score: Available
Developer organization: French Society for Palliative Care
This is a clinical practice guideline for patients who have bowel obstruction with advanced peritoneal carcinomatosis for which complete cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion are no longer relevant. The guideline provides recommendations on clinical assessment and treatment options for relieving intestinal obstruction or its symptoms. Treatment/management options include surgery, steroids, stents, nasogastric tubes (NGT's) and venting gastronomy, antisecretory drugs, and antiemetic management. Outcomes of interest include complication rate of surgical management (e.g. obstruction, perforation), morbi-mortality rates from surgery, and quality of life.

Management of Primary Cutaneous Squamous Cell Carcinoma

Year: 2014
AGREE II score: Available
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients over 18 years of age with primary invasive SCC cutaneous squamous cell carcinoma. The guideline reviews risk factors, staging, therapeutic interventions, and follow-up care. Outcomes of interest include prognostic factors, survival (five-year overall and recurrence free), local control, recurrence rate (regional and distant), nodal metastases, effectiveness of treatment, and adverse events.

Uveal Melanoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with malignant uveal melanoma. The guideline reviews diagnosis and work-up, primary management, adjuvant therapy, management of patients with metastatic disease, and management of high risk patients. Follow-up care is also discussed. Outcomes of interest include efficacy of treatments and imaging modalities.

The Society for Immunotherapy of Cancer Consensus Statement on Tumour Immunotherapy for the Treatment of Cutaneous Melanoma

Year: 2013
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
A clinical practice guideline for the treatment of cutaneous melanoma patients with tumour immunotherapy. The guideline examines the clinical application of immunotherapy with interferon‐α2b, pegylated‐interferon‐α2b, interleukin‐2 (IL‐2) and ipilimumab for high-risk, advanced-stage cancer. Outcomes of interest include decreasing the adverse effects of depression and improved therapeutic strategies with immunotherapy and standard radiation.

Malignant Melanoma S3-Guideline “Diagnosis, Therapy and Follow-up of Melanoma”

Year: 2013
AGREE II score: Unavailable
Developer organization: German Cancer Society (DKG)
This is a clinical practice guideline concerning the diagnosis, therapy and follow-up of melanoma. The guideline examines such treatment options as excision, adjuvant therapy with interferon-alpha, and lymphadenectomy. In addition, new immunotherapies such as the CTLA-4 antibody ipilimumab are considered, and follow-up procedures are discussed.

Management of Resectable Stage IV Primary Cutaneous Melanoma Without Nodal Disease

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with resectable stage IV primary cutaneous melanoma without nodal disease. The guideline examines treatment options, including chemoimmunotherapy and surgical resection of distant sites. Outcomes of interest include improved survival times and improved patient selection for chemoimmunotherapy.

European Guidelines for Topical Photodynamic Therapy Part 1: Treatment Delivery and Current Indications – Actinic Keratoses, Bowen’s Disease, Basal Cell Carcinoma

Year: 2013
AGREE II score: Unavailable
Developer organization: European Academy of Dermatology and Venereology
This is a clinical practice guideline for the delivery of topical photodynamic therapy (PDT) for certain non-melanoma skin cancers (NMSC). This guideline also considers the use of PDT in non-hyperkeratotic actinic keratoses, Bowen's disease, superficial basal cell carcinomas (BCC) and in certain thin nodular BCC. Additional topics discussed include: PDT photosensitizers, light sources and dosimetry, lesion preparation, as well as the potential adverse effects of PDT.

European Guidelines for Topical Photodynamic Therapy Part 2: Emerging Indications – Field Cancerization, Photorejuvenation and Inflammatory/Infective Dermatoses

Year: 2013
AGREE II score: Unavailable
Developer organization: European Academy of Dermatology and Venereology
This is a clinical practice guideline for photodynamic therapy (PDT) in the treatment, and possible prevention, of superficial skin cancers in immunosuppressed patients. The guideline considers PDT for the treatment of non-melanoma skin cancer in organ transplant recipients; PDT for field cancerization; as well as PDT for the prevention of non-melanoma skin cancer in organ transplant recipients. Other topics of interest include: topical PDT for infectious and inflammatory dermatoses acne; PDT for refractory hand and foot warts; as well as a discussion about the cost-effectiveness of PDT.

Systemic Adjuvant Therapy for Patient at High Risk for Recurrent Melanoma

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
A clinical practice guideline for adult patients with resected melanoma at high risk for recurrence. The guideline examines systemic therapy options, specifically with interferon, and highlights the importance of novel therapeutic trials. Outcomes of interest include improved melanoma staging and improved event-free survival.

Prevention of Skin Cancer

Year: 2013
AGREE II score: Available
Developer organization: Alberta Health Services
This is a clinical practice guideline for individuals at high risk of sustaining UV damage, leading to the development of skin cancer later in life. The guideline reviews risk assessment and sun protection strategies, and provides recommendations on counselling and interventions for limiting UV exposure in high-risk individuals, such as legislation on indoor tanning, policies on use of sun protection in high risk settings, social marketing and mass media campaigns, and education on sun protection. Outcomes of interest include effectiveness of interventions (measured by sunscreen use, use of hats, etc.), ultraviolet (UV) rates, and skin cancer rates.

Systemic Therapy for Unresectable Stage III or Metastatic Cutaneous Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for adult patients with metastatic or unresectable stage III melanoma with possible metastatic sites in distant skin, lymph nodes, liver, lungs, bone, and the brain. The guideline examines appropriate systemic therapies and dosing regimens for first- and second-line treatments. Outcomes of interest include improved survival outcomes and increased efficacy of combination therapies.

Optimal Excision Margins for Primary Cutaneous Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with malignant melanoma. The guideline discusses minimal optimal excision margins for melanoma, in general, with special consideration to melanomas of the face and distal extremities. Interventions considered include excisional biopsy, radiotherapy, topical imiquimod, Mohs micrographic surgery, sentinel node biopsy (SNB) and wide local excision. Outcomes of interest include survival, recurrence rate, and rate of local control.

Referral and Follow-up Surveillance of Cutaneous Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients 18 years of age or older with malignant melanoma. Referral of patients to the cancer treatment centre is reviewed and follow-up and surveillance are discussed, with stage-specific recommendations provided. Outcomes of interest include quality of life, overall survival, regional control, time and expense of surveillance, and test sensitivity and false positive rates.

Management of Squamous Cell Cancer of the Anal Canal

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with a primary diagnosis of biopsy-proven squamous cell cancer of the anal canal, including basaloid, cloacogenic, and transitional cell tumours. The guideline reviews treatment and follow-up care for squamous cell cancer, with radiotherapy and chemotherapy discussed as treatment options. Outcomes of interest include colostomy rate, local failure, survival, adverse effects (acute and late), and quality of life.

Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the Art and Recommendations

Year: 2013
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
A clinical practice guideline for the treatment of cutaneous melanoma patients with tumour immunotherapy. The guideline examines the clinical application of immunotherapy with interferon‐α2b, pegylated‐interferon‐α2b, interleukin‐2 (IL‐2) and ipilimumab for high-risk, advanced-stage cancer. Outcomes of interest include decreasing the adverse effects of depression and improved therapeutic strategies with immunotherapy and standard radiation.

Management of In-Transit Disease of the Limbs

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with melanoma with in-transit disease of the limbs. The guideline examines treatment options, including surgical resection and systemic therapy, depended on staging. Outcomes of interest include improved recommendations for isolated limb infusion, with no consensus on preferred systemic therapy.

Proton Beam Radiation Therapy

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews the use of proton beam radiation therapy to treat cancers in pediatric, adolescent, and adult patients. The guideline examines the benefits of proton beam radiation therapy for different cancer types, and discusses the referral and funding process for out-of-country treatment. Outcomes of interest include local control, survival (progression-free and overall), acute and late toxicities, and recurrence rates.

Biopsy of a Suspicious Pigmented Lesion

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients presenting with a mole or lesion that is suspicious for melanoma. The guideline examines biopsy techniques and diagnostic elements. Outcomes of interest include reducing misdiagnosis and testing inaccuracy.

Guidelines for the Management of Malignant Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
A clinical practice guideline for patients with malignant melanoma. The guideline examines management from diagnosis to follow-up, including referral processes, recommendations for pregnant patients, and supportive care. Outcomes of interest include improved recommendations for the timing and efficacy of sentinel lymph node biopsy, which is generally recommended as a first-line staging tool.

Preoperative and Pretreatment Investigations for Malignant Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients 18 years of age or older with malignant melanoma. The guideline reviews clinical presentation and preliminary work-up for malignant melanoma as well as additional work-up depending on stage. Outcomes of interest include cost-effectiveness, and specificity and sensitivity of diagnostic procedures.

Behavioral Counseling to Prevent Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement

Year: 2012
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
A clinical practice guideline examining the risks and benefits of providing skin care counseling to children and adults as a preventative measure for skin cancer. The guideline examines the effectiveness of behavioural change interventions and effective counseling interventions for multiple age brackets. Areas of focus include recommendations for individuals with fair skin and sun-protective behaviours.

Melanoma Guideline 2012

Year: 2012
AGREE II score: Unavailable
Developer organization: Integraal Kankercentrum Nederland
A clinical practice guideline for patients with melanoma of the skin. The guideline examines management and daily practice support for melanoma, including genetic risk-based screening, and appropriate excision. Outcomes of interest include reduced recurrence through larger excision margins and improved prevention recommendations.

Provincial Melanoma Treatment Guidelines

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with suspected or confirmed melanoma. The guideline examines management, including pathology, and imaging and treatment recommendations based on staging. Outcomes of interest include special considerations for Braff mutations and reduced unnecessary follow up testing.

Adjuvant Radiation for Malignant Melanoma

Year: 2012
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with malignant melanoma. The guideline discusses the use of adjuvant radiation therapy with consideration to cancer stage and whether the cancer being treated is recurrent. Contraindications are also reviewed. Outcomes of interest include survival and control rates.

Basal Cell Carcinoma, Squamous Cell Carcinoma (And Related Lesions) – A Guide to Clinical Management in Australia

Year: 2008
AGREE II score: Unavailable
Developer organization: Cancer Council Australia
A clinical practice guideline for patients with basal cell carcinoma, squamous cell carcinoma, and other keratinocyte tumours. The guideline examines multiple treatment options such as surgery, radiotherapy, cryotherapy and photodynamic therapy based on clinical presentation and prognosis. Outcomes of interest include primary prevention and improved lesion assessment.